Zydus forays into generics market of Japan
Cadila Healthcare Ltd on Monday announced the foray of Zydus group into the generic market of Japan and the establishment of a wholly owned subsidiary in the country.
By PTI |
MUMBAI: Cadila Healthcare Ltd on Monday announced the foray of Zydus group into the generic market of Japan and the establishment of a wholly owned subsidiary in the country.
The subsidiary, Zydus Pharma Inc, would market formulation generics and Active Pharmaceutical Ingredients in Japan, the company informed the Bombay Stock Exchange.
Zydus Pharma Inc would initiate the process for registration of products in 2007, besides marketing generics.
The company would also explore collaborations and alliances with Japanese pharmaceutical companies in areas such as joint research and development, co-marketing, contract manufacturing for Active Pharmaceutical Ingredients, intermediates and formulations, it said.
The subsidiary, headquartered at Shinjuku-ku in Tokyo, would be headed by Kazuhiro Kawabata as the President.
"Meeting healthcare needs with affordable, high quality therapies has been our constant endeavour. We have been engaged in building healthier communities globally and reaching out to people in the US, Europe, Latin America and across the world.
We now have an opportunity to extend our commitment to the people of Japan. We hope to do this by leveraging our strengths and expertise as a global healthcare provider and providing innovative healthcare solutions", Zydus Group Chairman and Managing Director Pankaj R Patel said.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
